Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Intravenous Immunoglobulin Nonresponsive Symptomatic Myocarditis during the Acute Stage of Incomplete Kawasaki Disease

불완전 가와사키병 급성기에 면역글로불린 치료에 반응하지 않는 유증상 심근염

  • Sohn, Youngsoo (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Kim, Yeo Hyang (Department of Pediatrics, Kyungpook National University School of Medicine)
  • 손영수 (경북대학교 의과대학 소아과학교실) ;
  • 김여향 (경북대학교 의과대학 소아과학교실)
  • Received : 2015.07.30
  • Accepted : 2015.09.10
  • Published : 2015.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

We report the case of a 7-year-old boy who showed treatment-nonresponsive hypotension (59/29 mmHg) and decreased left ventricular systolic function (fractional shortening 22%) in the acute stage of Kawasaki disease (KD). The present case serves to highlight that methylprednisolone pulse therapy should be considered in patients with intravenous immunoglobulin nonresponsive symptomatic myocarditis during the acute stage of KD.

저자들은 가와사키병 급성기에 치료에 반응하지 않은 저혈압(수축기 혈압 59 mmHg와 이완기 혈압 29 mmHg)과 수축기 심실 기능 부전(단축분획 22%)이 있던 7세 남아를 치료한 경험을 보고한다. 이 증례를 통해 가와사키병 급성기에 동반될 수 있는 유증상 심근염은 면역 글로블린 치료로 증상이 호전되지 않는 경우 스테로이드 펄스 요법이 필요함을 알 수 있다.

Keywords

References

  1. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J 2011;9:17. https://doi.org/10.1186/1546-0096-9-17
  2. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr 2004;16:508-14. https://doi.org/10.1097/01.mop.0000137796.23813.64
  3. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr Infect Dis J 2014;33:24-7. https://doi.org/10.1097/INF.0000000000000010
  4. Kuwabara M, Yashiro M, Kotani K, Tsuboi S, Ae R, Nakamura Y, et al. Cardiac lesions and initial laboratory data in Kawasaki disease: a nationwide survey in Japan. J Epidemiol 2015;25:189-93. https://doi.org/10.2188/jea.JE20140128
  5. Aggarwal P, Suri D, Narula N, Manojkumar R, Singh S. Symptomatic myocarditis in Kawasaki disease. Indian J Pediatr 2012;79:813-4. https://doi.org/10.1007/s12098-011-0552-4
  6. Yoshikawa H, Nomura Y, Masuda K, Hazeki D, Yotsumoto K, Arata M, et al. Four cases of Kawasaki syndrome complicated with myocarditis. Circ J 2006;70:202-5. https://doi.org/10.1253/circj.70.202
  7. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J 2011;32:2616-25. https://doi.org/10.1093/eurheartj/ehr165
  8. Rosenfeld EA, Shulman ST, Corydon KE, Mason W, Takahashi M, Kuroda C. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 1995;26:1000-3.
  9. Singh S, Rohit M, Gupta A, Suri D, Rawat A. Late symptomatic myocarditis in Kawasaki disease: an unusual manifestation. Indian J Pediatr 2014;81:404-5. https://doi.org/10.1007/s12098-014-1339-1
  10. Saneeymehri S, Baker K, So TY. Overview of pharmacological treatment options for pediatric patients with refractory kawasaki disease. J Pediatr Pharmacol Ther 2015;20:163-77.
  11. Fan PC, Chiu CH, Yen MH, Huang YC, Li CC, Lin TY. School-aged children with Kawasaki disease: high incidence of cervical lymphadenopathy and coronary artery involvement. J Paediatr Child Health 2003;39:55-7. https://doi.org/10.1046/j.1440-1754.2003.00085.x